Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601)
Summary Background The NEAT/BR9601 trial showed benefit for addition of anthracyclines to cyclophosphamide, methotrexate, and fluorouracil (CMF) as adjuvant treatment for early breast cancer. We investigated prospectively predictive biomarkers of anthracycline benefit including HER2 and TOP2A. Metho...
Saved in:
Published in | The lancet oncology Vol. 11; no. 3; pp. 266 - 274 |
---|---|
Main Authors | , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Elsevier Ltd
01.03.2010
Elsevier Limited |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Summary Background The NEAT/BR9601 trial showed benefit for addition of anthracyclines to cyclophosphamide, methotrexate, and fluorouracil (CMF) as adjuvant treatment for early breast cancer. We investigated prospectively predictive biomarkers of anthracycline benefit including HER2 and TOP2A. Methods 1941 tumours from 2391 women recruited to NEAT/BR9601 were analysed on tissue microarrays for HER2 and TOP2A amplification and deletion, HER1–3 and Ki67 expression, and duplication of chromosome 17 centromere enumeration probe (Ch17CEP). Log-rank analyses identified factors affecting relapse-free and overall survival, and regression models tested independent prognostic effect of markers, with adjustment for known prognostic factors (age, nodal status, oestrogen-receptor status, grade, and tumour size). The predictive value of markers was tested by treatment interactions for relapse-free and overall survival. Findings 1762 patients were analysed. 21% of tumours (n=367) were HER2 amplified, 10% were TOP2A amplified (n=169), 11% showed TOP2A deleted (n=191), 23% showed Ch17CEP duplication (n=406), and 61% had high (>13·0%) Ki67 (n=1136). In univariate analyses, only HER2 amplification and TOP2A deletion were significant prognostic factors for relapse-free (hazard ratio [HR] 1·59, 95% CI 1·32–1·92, p<0·0001; and 1·52, 1·20–1·92, p=0·0006, respectively) and overall survival (1·79, 1·47–2·19, p<0·0001; and 1·62, 1·26–2·08, p=0·0002 respectively). We detected no significant interaction with anthracycline benefit for Ki67, HER2, HER1–3 , or TOP2A . By contrast, in multivariate analyses, Ch17CEP duplication was associated with significant improvements in both relapse-free (HR 0·92, 95% CI 0·72–1·18 for tumours with normal Ch17CEP vs 0·52, 0·34–0·81 for tumours with abnormal Ch17CEP; p for interaction=0·004) and overall survival (0·94, 0·72–1·24 vs 0·57, 0·36–0·92; p for interaction=0·02) with anthracycline use. Interpretation In women with early breast cancer receiving adjuvant chemotherapy, the most powerful predictor of benefit from anthracyclines is Ch17CEP duplication. In view of the location of HER2/TOP2A on chromosome 17, Ch17CEP duplication might explain the inconsistencies in previous studies of factors predicting benefit from anthracyclines. Funding Cancer Research UK and the Scottish Breast Cancer Clinical Trials Group. |
---|---|
AbstractList | The NEAT/BR9601 trial showed benefit for addition of anthracyclines to cyclophosphamide, methotrexate, and fluorouracil (CMF) as adjuvant treatment for early breast cancer. We investigated prospectively predictive biomarkers of anthracycline benefit including
HER2 and
TOP2A.
1941 tumours from 2391 women recruited to NEAT/BR9601 were analysed on tissue microarrays for
HER2 and
TOP2A amplification and deletion,
HER1–3 and Ki67 expression, and duplication of chromosome 17 centromere enumeration probe (Ch17CEP). Log-rank analyses identified factors affecting relapse-free and overall survival, and regression models tested independent prognostic effect of markers, with adjustment for known prognostic factors (age, nodal status, oestrogen-receptor status, grade, and tumour size). The predictive value of markers was tested by treatment interactions for relapse-free and overall survival.
1762 patients were analysed. 21% of tumours (n=367) were
HER2 amplified, 10% were
TOP2A amplified (n=169), 11% showed
TOP2A deleted (n=191), 23% showed Ch17CEP duplication (n=406), and 61% had high (>13·0%) Ki67 (n=1136). In univariate analyses, only
HER2 amplification and
TOP2A deletion were significant prognostic factors for relapse-free (hazard ratio [HR] 1·59, 95% CI 1·32–1·92, p<0·0001; and 1·52, 1·20–1·92, p=0·0006, respectively) and overall survival (1·79, 1·47–2·19, p<0·0001; and 1·62, 1·26–2·08, p=0·0002 respectively). We detected no significant interaction with anthracycline benefit for Ki67,
HER2, HER1–3, or
TOP2A. By contrast, in multivariate analyses, Ch17CEP duplication was associated with significant improvements in both relapse-free (HR 0·92, 95% CI 0·72–1·18 for tumours with normal Ch17CEP
vs 0·52, 0·34–0·81 for tumours with abnormal Ch17CEP; p for interaction=0·004) and overall survival (0·94, 0·72–1·24
vs 0·57, 0·36–0·92; p for interaction=0·02) with anthracycline use.
In women with early breast cancer receiving adjuvant chemotherapy, the most powerful predictor of benefit from anthracyclines is Ch17CEP duplication. In view of the location of
HER2/TOP2A on chromosome 17, Ch17CEP duplication might explain the inconsistencies in previous studies of factors predicting benefit from anthracyclines.
Cancer Research UK and the Scottish Breast Cancer Clinical Trials Group. The NEAT/BR9601 trial showed benefit for addition of anthracyclines to cyclophosphamide, methotrexate, and fluorouracil (CMF) as adjuvant treatment for early breast cancer. We investigated prospectively predictive biomarkers of anthracycline benefit including HER2 and TOP2A. 1941 tumours from 2391 women recruited to NEAT/BR9601 were analysed on tissue microarrays for HER2 and TOP2A amplification and deletion, HER1-3 and Ki67 expression, and duplication of chromosome 17 centromere enumeration probe (Ch17CEP). Log-rank analyses identified factors affecting relapse-free and overall survival, and regression models tested independent prognostic effect of markers, with adjustment for known prognostic factors (age, nodal status, oestrogen-receptor status, grade, and tumour size). The predictive value of markers was tested by treatment interactions for relapse-free and overall survival. 1762 patients were analysed. 21% of tumours (n=367) were HER2 amplified, 10% were TOP2A amplified (n=169), 11% showed TOP2A deleted (n=191), 23% showed Ch17CEP duplication (n=406), and 61% had high (>13.0%) Ki67 (n=1136). In univariate analyses, only HER2 amplification and TOP2A deletion were significant prognostic factors for relapse-free (hazard ratio [HR] 1.59, 95% CI 1.32-1.92, p<0.0001; and 1.52, 1.20-1.92, p=0.0006, respectively) and overall survival (1.79, 1.47-2.19, p<0.0001; and 1.62, 1.26-2.08, p=0.0002 respectively). We detected no significant interaction with anthracycline benefit for Ki67, HER2, HER1-3, or TOP2A. By contrast, in multivariate analyses, Ch17CEP duplication was associated with significant improvements in both relapse-free (HR 0.92, 95% CI 0.72-1.18 for tumours with normal Ch17CEP vs 0.52, 0.34-0.81 for tumours with abnormal Ch17CEP; p for interaction=0.004) and overall survival (0.94, 0.72-1.24 vs 0.57, 0.36-0.92; p for interaction=0.02) with anthracycline use. In women with early breast cancer receiving adjuvant chemotherapy, the most powerful predictor of benefit from anthracyclines is Ch17CEP duplication. In view of the location of HER2/TOP2A on chromosome 17, Ch17CEP duplication might explain the inconsistencies in previous studies of factors predicting benefit from anthracyclines. Cancer Research UK and the Scottish Breast Cancer Clinical Trials Group. The NEAT/BR9601 trial showed benefit for addition of anthracyclines to cyclophosphamide, methotrexate, and fluorouracil (CMF) as adjuvant treatment for early breast cancer. We investigated prospectively predictive biomarkers of anthracycline benefit including HER2 and TOP2A. 1941 tumours from 2391 women recruited to NEAT/BR9601 were analysed on tissue microarrays for HER2 and TOP2A amplification and deletion, HER1-3 and Ki67 expression, and duplication of chromosome 17 centromere enumeration probe (Ch17CEP). Log-rank analyses identified factors affecting relapse-free and overall survival, and regression models tested independent prognostic effect of markers, with adjustment for known prognostic factors (age, nodal status, oestrogen-receptor status, grade, and tumour size). The predictive value of markers was tested by treatment interactions for relapse-free and overall survival. 1762 patients were analysed. 21% of tumours (n=367) were HER2 amplified, 10% were TOP2A amplified (n=169), 11% showed TOP2A deleted (n=191), 23% showed Ch17CEP duplication (n=406), and 61% had high (>13.0%) Ki67 (n=1136). In univariate analyses, only HER2 amplification and TOP2A deletion were significant prognostic factors for relapse-free (hazard ratio [HR] 1.59, 95% CI 1.32-1.92, p<0.0001; and 1.52, 1.20-1.92, p=0.0006, respectively) and overall survival (1.79, 1.47-2.19, p<0.0001; and 1.62, 1.26-2.08, p=0.0002 respectively). We detected no significant interaction with anthracycline benefit for Ki67, HER2, HER1-3, or TOP2A. By contrast, in multivariate analyses, Ch17CEP duplication was associated with significant improvements in both relapse-free (HR 0.92, 95% CI 0.72-1.18 for tumours with normal Ch17CEP vs 0.52, 0.34-0.81 for tumours with abnormal Ch17CEP; p for interaction=0.004) and overall survival (0.94, 0.72-1.24 vs 0.57, 0.36-0.92; p for interaction=0.02) with anthracycline use. In women with early breast cancer receiving adjuvant chemotherapy, the most powerful predictor of benefit from anthracyclines is Ch17CEP duplication. In view of the location of HER2/TOP2A on chromosome 17, Ch17CEP duplication might explain the inconsistencies in previous studies of factors predicting benefit from anthracyclines. Cancer Research UK and the Scottish Breast Cancer Clinical Trials Group. Summary Background The NEAT/BR9601 trial showed benefit for addition of anthracyclines to cyclophosphamide, methotrexate, and fluorouracil (CMF) as adjuvant treatment for early breast cancer. We investigated prospectively predictive biomarkers of anthracycline benefit including HER2 and TOP2A. Methods 1941 tumours from 2391 women recruited to NEAT/BR9601 were analysed on tissue microarrays for HER2 and TOP2A amplification and deletion, HER1–3 and Ki67 expression, and duplication of chromosome 17 centromere enumeration probe (Ch17CEP). Log-rank analyses identified factors affecting relapse-free and overall survival, and regression models tested independent prognostic effect of markers, with adjustment for known prognostic factors (age, nodal status, oestrogen-receptor status, grade, and tumour size). The predictive value of markers was tested by treatment interactions for relapse-free and overall survival. Findings 1762 patients were analysed. 21% of tumours (n=367) were HER2 amplified, 10% were TOP2A amplified (n=169), 11% showed TOP2A deleted (n=191), 23% showed Ch17CEP duplication (n=406), and 61% had high (>13·0%) Ki67 (n=1136). In univariate analyses, only HER2 amplification and TOP2A deletion were significant prognostic factors for relapse-free (hazard ratio [HR] 1·59, 95% CI 1·32–1·92, p<0·0001; and 1·52, 1·20–1·92, p=0·0006, respectively) and overall survival (1·79, 1·47–2·19, p<0·0001; and 1·62, 1·26–2·08, p=0·0002 respectively). We detected no significant interaction with anthracycline benefit for Ki67, HER2, HER1–3 , or TOP2A . By contrast, in multivariate analyses, Ch17CEP duplication was associated with significant improvements in both relapse-free (HR 0·92, 95% CI 0·72–1·18 for tumours with normal Ch17CEP vs 0·52, 0·34–0·81 for tumours with abnormal Ch17CEP; p for interaction=0·004) and overall survival (0·94, 0·72–1·24 vs 0·57, 0·36–0·92; p for interaction=0·02) with anthracycline use. Interpretation In women with early breast cancer receiving adjuvant chemotherapy, the most powerful predictor of benefit from anthracyclines is Ch17CEP duplication. In view of the location of HER2/TOP2A on chromosome 17, Ch17CEP duplication might explain the inconsistencies in previous studies of factors predicting benefit from anthracyclines. Funding Cancer Research UK and the Scottish Breast Cancer Clinical Trials Group. |
Author | Provenzano, Elena, MBBS Poole, Christopher J, Prof Caldas, Carlos, Prof Hiller, Louise, PhD Twelves, Chris J, Prof Dunn, Janet A, PhD Munro, Alison F, MSc Campbell, Fiona M, MSc Rea, Daniel W, PhD Pharoah, Paul, BMBCh Jordan, Sarah, MSc Earl, Helena, MBBS Cameron, David A, Prof Bartlett, John MS, Prof McConkey, Christopher, MSc Thomas, Jeremy, MBBS |
Author_xml | – sequence: 1 fullname: Bartlett, John MS, Prof – sequence: 2 fullname: Munro, Alison F, MSc – sequence: 3 fullname: Dunn, Janet A, PhD – sequence: 4 fullname: McConkey, Christopher, MSc – sequence: 5 fullname: Jordan, Sarah, MSc – sequence: 6 fullname: Twelves, Chris J, Prof – sequence: 7 fullname: Cameron, David A, Prof – sequence: 8 fullname: Thomas, Jeremy, MBBS – sequence: 9 fullname: Campbell, Fiona M, MSc – sequence: 10 fullname: Rea, Daniel W, PhD – sequence: 11 fullname: Provenzano, Elena, MBBS – sequence: 12 fullname: Caldas, Carlos, Prof – sequence: 13 fullname: Pharoah, Paul, BMBCh – sequence: 14 fullname: Hiller, Louise, PhD – sequence: 15 fullname: Earl, Helena, MBBS – sequence: 16 fullname: Poole, Christopher J, Prof |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/20079691$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkc1u1TAQhS1URH_gEUAWq3YROo6TOGEBulQXiqjaCm7XluNMVN-mTrCTK-UN-th1ktJFN6xsjc-c8fnmkOzZ1iIh7xl8YsCy0z8sERDFkKTHDE4EAGQRe0UOQjmJ0iTP9-b7Itknh95vAZhgkL4h-zGAKLKCHZCHa4eV0b3ZIb1X7g6dp21Nle1vndKjboxFWqLF2vSfqaKda32Hs74Zadcoa7EKctWM3syt_S3Sm1_0UvWmDWW67owbSqONpatqO-yCNd04E16OL9erzem330UG7OQteV2rxuO7p_OI3Hxfb87Oo4urHz_PVheRTpO0j3ghIC_zOFZCMV7wpFKiyGutecax5JyHWCqLuSi4iFWdIda5qjnwskbFU86PyMfFNyT5O6Dv5bYdXPiol4FKkQqWsyBKF5EOcb3DWnbOBDyjZCAn_HLGLye2U2nGL6e-D0_mQ3mP1XPXP95B8HURYIi4M-ik1watDjtwgaqsWvPfEV9eOEw7Mlo1dziifw7DpI8lLCaTB4PZgfFHI4iqXg |
CODEN | LANCAO |
CitedBy_id | crossref_primary_10_1177_1078155214531513 crossref_primary_10_1016_S1470_2045_11_70231_5 crossref_primary_10_18632_oncotarget_5562 crossref_primary_10_1007_s10549_011_1896_1 crossref_primary_10_1007_s12253_012_9518_8 crossref_primary_10_1002_cam4_1730 crossref_primary_10_3892_mco_2017_1463 crossref_primary_10_1016_S0959_8049_11_70211_8 crossref_primary_10_3390_ijms25084478 crossref_primary_10_1186_bcr2568 crossref_primary_10_12677_MD_2016_64016 crossref_primary_10_3109_07357907_2012_725441 crossref_primary_10_1007_s11864_018_0547_8 crossref_primary_10_1056_NEJMc1100069 crossref_primary_10_1016_j_humpath_2011_08_018 crossref_primary_10_1016_j_breast_2011_03_002 crossref_primary_10_3389_fonc_2021_774088 crossref_primary_10_1016_j_humpath_2016_12_004 crossref_primary_10_1309_AJCP0EN6AQMWETZZ crossref_primary_10_1007_s10549_016_3824_x crossref_primary_10_1007_s10549_019_05148_5 crossref_primary_10_1007_s12094_012_0779_1 crossref_primary_10_1016_j_breast_2016_11_011 crossref_primary_10_4048_jbc_2012_15_1_24 crossref_primary_10_1016_S1470_2045_10_70020_6 crossref_primary_10_1007_s10549_010_0985_x crossref_primary_10_2217_fon_10_163 crossref_primary_10_3390_cancers14092114 crossref_primary_10_1038_bjc_2012_370 crossref_primary_10_1002_ijc_28150 crossref_primary_10_1111_his_14728 crossref_primary_10_3390_jcm9103079 crossref_primary_10_1007_s10577_023_09737_5 crossref_primary_10_3390_cancers11081149 crossref_primary_10_3892_or_2017_5553 crossref_primary_10_1007_s13402_013_0165_1 crossref_primary_10_1186_s12967_017_1134_7 crossref_primary_10_2217_bmm_10_73 crossref_primary_10_1111_tbj_12124 crossref_primary_10_1186_bcr2824 crossref_primary_10_1200_JCO_2013_54_7869 crossref_primary_10_1002_ijc_27997 crossref_primary_10_1007_s00129_015_3802_0 crossref_primary_10_1007_s00292_012_1645_1 crossref_primary_10_1007_s10549_010_0931_y crossref_primary_10_1016_S0960_9776_11_70311_3 crossref_primary_10_4132_jptm_2019_11_03 crossref_primary_10_1038_s41523_021_00342_5 crossref_primary_10_1111_j_1749_6632_2010_05776_x crossref_primary_10_1097_PAI_0000000000000154 crossref_primary_10_2217_fon_13_103 crossref_primary_10_1007_s10549_011_1837_z crossref_primary_10_1007_s12254_012_0027_y crossref_primary_10_2165_11595110_000000000_00000 crossref_primary_10_1038_bjc_2012_232 crossref_primary_10_1186_1471_2407_13_163 crossref_primary_10_1016_S1359_6349_11_70005_2 crossref_primary_10_1016_j_prp_2014_06_017 crossref_primary_10_1200_JCO_2009_27_5644 crossref_primary_10_1186_bcr3051 crossref_primary_10_1038_onc_2010_286 crossref_primary_10_1371_journal_pone_0164013 crossref_primary_10_1007_s10549_015_3310_x crossref_primary_10_1186_1479_5876_10_212 crossref_primary_10_1007_s10549_011_1840_4 crossref_primary_10_1111_his_12336 crossref_primary_10_1038_sj_bjc_6605627 crossref_primary_10_1002_jcb_22781 crossref_primary_10_1093_annonc_mdr519 crossref_primary_10_1111_j_1365_2559_2011_04067_x crossref_primary_10_3390_cancers12040824 crossref_primary_10_1186_bcr2752 crossref_primary_10_1073_pnas_2209856120 crossref_primary_10_1586_17512433_2014_945429 crossref_primary_10_1097_MD_0000000000012908 crossref_primary_10_1016_j_molonc_2011_11_006 crossref_primary_10_1007_s10549_013_2819_0 crossref_primary_10_1186_1479_5876_10_10 crossref_primary_10_3816_CBC_2010_s_017 crossref_primary_10_1016_j_neo_2014_08_012 crossref_primary_10_1136_jclinpath_2013_201506 crossref_primary_10_2217_fon_10_56 crossref_primary_10_18632_oncotarget_21579 crossref_primary_10_1038_s41598_019_54471_w crossref_primary_10_1097_PAT_0b013e3283430926 crossref_primary_10_1590_1414_431X20132483 crossref_primary_10_18632_oncotarget_8542 crossref_primary_10_1016_j_tranon_2017_05_006 crossref_primary_10_1002_cncr_25580 crossref_primary_10_1007_s12282_011_0263_8 crossref_primary_10_1016_j_bbcan_2013_04_004 crossref_primary_10_1007_s10549_010_0744_z crossref_primary_10_1038_nrclinonc_2015_46 crossref_primary_10_1200_JCO_2011_35_2468 crossref_primary_10_1200_JCO_2012_42_8896 crossref_primary_10_1158_1078_0432_CCR_10_0773 crossref_primary_10_1186_bcr3147 crossref_primary_10_3389_fonc_2023_1067735 |
Cites_doi | 10.1056/NEJMoa052084 10.1200/JCO.2007.11.0973 10.1200/JCO.2007.15.1712 10.2217/17520363.2.4.397 10.1023/A:1021399923825 10.1074/mcp.R400001-MCP200 10.1200/JCO.2007.14.6597 10.1056/NEJMoa054504 10.1023/B:BREA.0000036783.88387.47 10.1016/j.canlet.2008.01.015 10.1159/000107583 10.1200/JCO.2003.04.021 10.1002/path.971 10.1016/S0002-9440(10)64952-8 10.1158/0008-5472.SABCS-705 10.1200/JCO.2007.15.4716 10.1093/jnci/djp067 10.1093/jnci/djm252 10.1038/sj.bjc.6602678 10.1158/1078-0432.CCR-05-0196 10.1016/j.ejca.2008.09.014 10.1200/JCO.2005.11.007 10.1038/35021093 10.1038/modpathol.3880505 10.1056/NEJMe068065 10.1093/jnci/92.24.1991 10.1023/A:1011669223035 10.1111/j.1365-2559.2006.02412.x 10.1038/modpathol.2009.78 10.1038/nature04689 10.1002/(SICI)1097-0258(20000229)19:4<441::AID-SIM349>3.0.CO;2-N 10.1002/path.2574 10.1158/0008-5472.SABCS-6059 |
ContentType | Journal Article |
Copyright | Elsevier Ltd 2010 Elsevier Ltd Copyright 2010 Elsevier Ltd. All rights reserved. Copyright Elsevier Limited Mar 2010 |
Copyright_xml | – notice: Elsevier Ltd – notice: 2010 Elsevier Ltd – notice: Copyright 2010 Elsevier Ltd. All rights reserved. – notice: Copyright Elsevier Limited Mar 2010 |
DBID | 6I. AAFTH CGR CUY CVF ECM EIF NPM AAYXX CITATION 0TZ 3V. 7RV 7TO 7X7 7XB 88E 8AO 8C1 8C2 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH H94 K9. KB0 M0S M1P NAPCQ PQEST PQQKQ PQUKI |
DOI | 10.1016/S1470-2045(10)70006-1 |
DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Pharma and Biotech Premium PRO ProQuest Central (Corporate) Nursing & Allied Health Database (ProQuest) Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database (Proquest) Lancet Titles Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni Edition) Medical Database Nursing & Allied Health Premium ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Pharma and Biotech Premium PRO Oncogenes and Growth Factors Abstracts Lancet Titles ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Pharma Collection ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) AIDS and Cancer Research Abstracts ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest Central (Alumni) |
DatabaseTitleList | MEDLINE Pharma and Biotech Premium PRO |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1474-5488 |
EndPage | 274 |
ExternalDocumentID | 1978375891 10_1016_S1470_2045_10_70006_1 20079691 S1470204510700061 1_s2_0_S1470204510700061 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GeographicLocations | United Kingdom--UK |
GeographicLocations_xml | – name: United Kingdom--UK |
GrantInformation | Cancer Research UK and the Scottish Breast Cancer Clinical Trials Group. |
GrantInformation_xml | – fundername: Cancer Research UK grantid: 10119 – fundername: Cancer Research UK grantid: A10119 |
GroupedDBID | --- --K --M -RU .1- .55 .FO 0R~ 123 1B1 1P~ 1~5 29L 3V. 4.4 457 4CK 4G. 53G 5VS 6PF 7-5 71M 7RV 7X7 88E 8AO 8C1 8C2 8FI 8FJ AACTN AAEDT AAEDW AAIKJ AAKOC AALRI AAMRU AAQFI AAQQT AAQXK AAWTL AAXKI AAXUO ABBQC ABMAC ABMZM ABUWG ACGFS ACPRK ACRLP ADBBV ADMUD AEKER AENEX AEVXI AFCTW AFKRA AFKWA AFRHN AFTJW AFXIZ AGHFR AHMBA AITUG AJOXV AJRQY AJUYK AKRWK ALIPV ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BENPR BKEYQ BKOJK BNPGV BPHCQ BVXVI CCPQU CS3 DU5 EBS EFJIC EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-Q GBLVA HVGLF HZ~ IHE J1W KOM M1P M41 MO0 N9A NAPCQ O-L O9- OC~ OO- OZT P-8 P-9 P2P PCD PQQKQ PROAC PSQYO R2- RIG ROL RPZ SDF SDG SEL SES SPCBC SSH SSZ T5K TLN UV1 WOW X7M XBR Z5R 6I. AAFTH ABLVK ABYKQ AHPSJ AJBFU HMCUK UKHRP ZA5 CGR CUY CVF ECM EIF NPM AAYXX ACRPL CITATION 0TZ 7TO 7XB 8FK H94 K9. PQEST PQUKI |
ID | FETCH-LOGICAL-c545t-39708b822a7a13934da798fcc363eb333969a62379372af6eef8af303bfea3533 |
IEDL.DBID | 8C1 |
ISSN | 1470-2045 |
IngestDate | Thu Oct 10 22:15:38 EDT 2024 Fri Dec 06 05:50:43 EST 2024 Sat Nov 02 12:25:13 EDT 2024 Fri Feb 23 02:29:55 EST 2024 Tue Oct 15 22:58:27 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Language | English |
License | http://creativecommons.org/licenses/by/4.0 Copyright 2010 Elsevier Ltd. All rights reserved. https://www.elsevier.com/tdm/userlicense/1.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c545t-39708b822a7a13934da798fcc363eb333969a62379372af6eef8af303bfea3533 |
OpenAccessLink | https://dx.doi.org/10.1016/S1470-2045(10)70006-1 |
PMID | 20079691 |
PQID | 200957181 |
PQPubID | 46089 |
PageCount | 9 |
ParticipantIDs | proquest_journals_200957181 crossref_primary_10_1016_S1470_2045_10_70006_1 pubmed_primary_20079691 elsevier_sciencedirect_doi_10_1016_S1470_2045_10_70006_1 elsevier_clinicalkeyesjournals_1_s2_0_S1470204510700061 |
PublicationCentury | 2000 |
PublicationDate | 2010-03-01 |
PublicationDateYYYYMMDD | 2010-03-01 |
PublicationDate_xml | – month: 03 year: 2010 text: 2010-03-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | The lancet oncology |
PublicationTitleAlternate | Lancet Oncol |
PublicationYear | 2010 |
Publisher | Elsevier Ltd Elsevier Limited |
Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited |
References | Kirkegaard, Edwards, Tovey (bib16) 2006; 48 Bartlett, Munro, Cameron, Thomas, Prescott, Twelves (bib12) 2008; 26 Knoop, Knudsen, Balslev (bib22) 2005; 23 Gennari, Sormani, Pronzato (bib29) 2008; 100 Tovey, Dunne, Witton, Forsyth, Cooke, Bartlett (bib3) 2005; 11 Wang, Saboorian, Frenkel (bib35) 2002; 15 Moliterni, Menard, Valagussa (bib33) 2003; 21 Di Leo, Gancberg, Larsimont (bib27) 2002; 8 Perou, Sorlie, Eisen (bib1) 2000; 406 Jarvinen, Tanner, Rantanen (bib34) 2000; 156 Di Leo, Chan, Paesmans (bib23) 2004; 86 Ross, Fletcher, Bloom (bib7) 2004; 3 Di Leo, Biganzoli, Claudino, Licitra, Pestrin, Larsimont (bib20) 2008; 44 Poole, Earl, Hiller (bib14) 2006; 355 Miyoshi, Kurosumi, Kurebayashi (bib5) 2008; 264 Bartlett, Desmedt, Munro (bib24) 2009; 69 De Laurentiis, Caputo, Massarelli (bib31) 2001; 20 Bartlett, Ellis, Dowsett (bib4) 2007; 25 Paik, Bryant, Tan-Chiu (bib32) 2000; 92 Spears, Kenicer, Munro, Bartlett (bib2) 2008; 2 Zody, Garber, Adams (bib11) 2006; 440 Jarvinen, Kononen, Peltohuikko, Isola (bib8) 1996; 148 Watters, Going, Cooke, Bartlett (bib9) 2003; 77 Di Leo, Isola, Piette (bib30) 2009; 69 O'Malley, Chia, Tu (bib25) 2009; 101 Piccart-Gebhart (bib21) 2006; 354 Leyland-Jones, Ambrosone, Bartlett (bib15) 2008; 26 Yeh, Martin, Robetorye (bib10) 2009; 22 Di Leo, Larsimont, Gancberg (bib28) 2001; 12 Schmoor, Sauerbrei, Schumacher (bib18) 2000; 19 McShane, Altman, Sauerbrei, Taube, Gion, Clark (bib19) 2006; 93 Marchiò, Lambros, Gugliotta (bib36) 2009; 219 Pritchard, Shepherd, O'Malley (bib26) 2006; 354 Pritchard, Messersmith, Elavathil, Trudeau, O'Malley, Dhesy-Thind (bib6) 2008; 26 Corzo, Bellosillo, Corominas (bib13) 2007; 28 Bartlett, Going, Mallon (bib17) 2001; 195 20202603 - Lancet Oncol. 2010 Mar;11(3):216-7 McShane (10.1016/S1470-2045(10)70006-1_bib19) 2006; 93 Corzo (10.1016/S1470-2045(10)70006-1_bib13) 2007; 28 Di Leo (10.1016/S1470-2045(10)70006-1_bib20) 2008; 44 Bartlett (10.1016/S1470-2045(10)70006-1_bib24) 2009; 69 Spears (10.1016/S1470-2045(10)70006-1_bib2) 2008; 2 Knoop (10.1016/S1470-2045(10)70006-1_bib22) 2005; 23 Bartlett (10.1016/S1470-2045(10)70006-1_bib12) 2008; 26 Di Leo (10.1016/S1470-2045(10)70006-1_bib23) 2004; 86 Yeh (10.1016/S1470-2045(10)70006-1_bib10) 2009; 22 Poole (10.1016/S1470-2045(10)70006-1_bib14) 2006; 355 Di Leo (10.1016/S1470-2045(10)70006-1_bib28) 2001; 12 Di Leo (10.1016/S1470-2045(10)70006-1_bib30) 2009; 69 Marchiò (10.1016/S1470-2045(10)70006-1_bib36) 2009; 219 Jarvinen (10.1016/S1470-2045(10)70006-1_bib8) 1996; 148 Piccart-Gebhart (10.1016/S1470-2045(10)70006-1_bib21) 2006; 354 Bartlett (10.1016/S1470-2045(10)70006-1_bib17) 2001; 195 O'Malley (10.1016/S1470-2045(10)70006-1_bib25) 2009; 101 Bartlett (10.1016/S1470-2045(10)70006-1_bib4) 2007; 25 Leyland-Jones (10.1016/S1470-2045(10)70006-1_bib15) 2008; 26 Pritchard (10.1016/S1470-2045(10)70006-1_bib26) 2006; 354 Miyoshi (10.1016/S1470-2045(10)70006-1_bib5) 2008; 264 Kirkegaard (10.1016/S1470-2045(10)70006-1_bib16) 2006; 48 Jarvinen (10.1016/S1470-2045(10)70006-1_bib34) 2000; 156 Zody (10.1016/S1470-2045(10)70006-1_bib11) 2006; 440 Paik (10.1016/S1470-2045(10)70006-1_bib32) 2000; 92 Watters (10.1016/S1470-2045(10)70006-1_bib9) 2003; 77 Perou (10.1016/S1470-2045(10)70006-1_bib1) 2000; 406 De Laurentiis (10.1016/S1470-2045(10)70006-1_bib31) 2001; 20 Schmoor (10.1016/S1470-2045(10)70006-1_bib18) 2000; 19 Wang (10.1016/S1470-2045(10)70006-1_bib35) 2002; 15 Tovey (10.1016/S1470-2045(10)70006-1_bib3) 2005; 11 Moliterni (10.1016/S1470-2045(10)70006-1_bib33) 2003; 21 Pritchard (10.1016/S1470-2045(10)70006-1_bib6) 2008; 26 Di Leo (10.1016/S1470-2045(10)70006-1_bib27) 2002; 8 Gennari (10.1016/S1470-2045(10)70006-1_bib29) 2008; 100 Ross (10.1016/S1470-2045(10)70006-1_bib7) 2004; 3 |
References_xml | – volume: 25 start-page: 4423 year: 2007 end-page: 4430 ident: bib4 article-title: Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy publication-title: J Clin Oncol contributor: fullname: Dowsett – volume: 20 start-page: 133 year: 2001 ident: bib31 article-title: HER2 expression and anthracycline effect: results from the Naples GUN3 Randomized Trial publication-title: Proc Am Soc Clin Oncol contributor: fullname: Massarelli – volume: 2 start-page: 397 year: 2008 end-page: 407 ident: bib2 article-title: Type I receptor tyrosine kinases as predictive or prognostic markers in early breast cancer publication-title: Biomarker Med contributor: fullname: Bartlett – volume: 77 start-page: 109 year: 2003 end-page: 114 ident: bib9 article-title: Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma publication-title: Breast Cancer Res Treat contributor: fullname: Bartlett – volume: 156 start-page: 839 year: 2000 end-page: 847 ident: bib34 article-title: Amplification and deletion of topoisomerase II alpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer publication-title: Am J Pathol contributor: fullname: Rantanen – volume: 11 start-page: 4835 year: 2005 end-page: 4842 ident: bib3 article-title: Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer? publication-title: Clin Cancer Res contributor: fullname: Bartlett – volume: 354 start-page: 2177 year: 2006 end-page: 2179 ident: bib21 article-title: Anthracyclines and the tailoring of treatment for early breast cancer publication-title: N Engl J Med contributor: fullname: Piccart-Gebhart – volume: 8 start-page: 1107 year: 2002 end-page: 1116 ident: bib27 article-title: HER-2 amplification and topoisomerase II{alpha} gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil publication-title: Clin Cancer Res contributor: fullname: Larsimont – volume: 354 start-page: 2103 year: 2006 end-page: 2111 ident: bib26 article-title: HER2 and responsiveness of breast cancer to adjuvant chemotherapy publication-title: N Engl J Med contributor: fullname: O'Malley – volume: 148 start-page: 2073 year: 1996 end-page: 2082 ident: bib8 article-title: Expression of topoisomerase II alpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer publication-title: Am J Pathol contributor: fullname: Isola – volume: 26 start-page: 5027 year: 2008 end-page: 5035 ident: bib12 article-title: Type I receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial publication-title: J Clin Oncol contributor: fullname: Twelves – volume: 92 start-page: 1991 year: 2000 end-page: 1998 ident: bib32 article-title: HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15 publication-title: J Natl Cancer Inst contributor: fullname: Tan-Chiu – volume: 100 start-page: 14 year: 2008 end-page: 20 ident: bib29 article-title: HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials publication-title: J Natl Cancer Inst contributor: fullname: Pronzato – volume: 355 start-page: 1851 year: 2006 end-page: 1862 ident: bib14 article-title: Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer publication-title: N Engl J Med contributor: fullname: Hiller – volume: 86 start-page: 197 year: 2004 end-page: 206 ident: bib23 article-title: HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel publication-title: Breast Cancer Res Treat contributor: fullname: Paesmans – volume: 26 start-page: 5638 year: 2008 end-page: 5644 ident: bib15 article-title: Recommendations for collection and handling of specimens from group breast cancer clinical trials publication-title: J Clin Oncol contributor: fullname: Bartlett – volume: 264 start-page: 44 year: 2008 end-page: 53 ident: bib5 article-title: Topoisomerase II alpha-positive and BRCA1-negative phenotype: association with favorable response to epirubicin-based regimens for human breast cancers publication-title: Cancer Letts contributor: fullname: Kurebayashi – volume: 219 start-page: 16 year: 2009 end-page: 24 ident: bib36 article-title: Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis publication-title: J Pathol contributor: fullname: Gugliotta – volume: 93 start-page: 387 year: 2006 end-page: 391 ident: bib19 article-title: REporting recommendations for tumour MARKer prognostic studies (REMARK) publication-title: Br J Cancer contributor: fullname: Clark – volume: 69 start-page: 99S year: 2009 ident: bib30 article-title: A meta-analysis of phase III trials evaluating the predictive value of HER2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy publication-title: Cancer Res contributor: fullname: Piette – volume: 21 start-page: 458 year: 2003 end-page: 462 ident: bib33 article-title: HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer publication-title: J Clin Oncol contributor: fullname: Valagussa – volume: 23 start-page: 7483 year: 2005 end-page: 7490 ident: bib22 article-title: Retrospective analysis of topoismerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin and fluorouracil: Danish breast cancer cooperative group publication-title: J Clin Oncol contributor: fullname: Balslev – volume: 26 start-page: 736 year: 2008 end-page: 744 ident: bib6 article-title: HER-2 and topoisomerase II as predictors of response to chemotherapy publication-title: J Clin Oncol contributor: fullname: Dhesy-Thind – volume: 195 start-page: 422 year: 2001 end-page: 428 ident: bib17 article-title: Evaluating HER2 amplification and overexpression in breast cancer publication-title: J Pathol contributor: fullname: Mallon – volume: 440 start-page: 1045 year: 2006 end-page: 1049 ident: bib11 article-title: DNA sequence of human chromosome 17 and analysis of rearrangement in the human lineage publication-title: Nature contributor: fullname: Adams – volume: 19 start-page: 441 year: 2000 end-page: 452 ident: bib18 article-title: Sample size considerations for the evaluation of prognostic factors in survival analysis publication-title: Stat Med contributor: fullname: Schumacher – volume: 101 start-page: 644 year: 2009 end-page: 650 ident: bib25 article-title: Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy publication-title: J Natl Cancer Inst contributor: fullname: Tu – volume: 44 start-page: 2791 year: 2008 end-page: 2798 ident: bib20 article-title: Topoisomerase II alpha as a marker predicting anthracyclines' activity in early breast cancer patients: Ready for the primetime? publication-title: Eur J Cancer contributor: fullname: Larsimont – volume: 406 start-page: 747 year: 2000 end-page: 752 ident: bib1 article-title: Molecular portraits of human breast tumours publication-title: Nature contributor: fullname: Eisen – volume: 22 start-page: 1169 year: 2009 end-page: 1175 ident: bib10 article-title: Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event publication-title: Mod Pathol contributor: fullname: Robetorye – volume: 69 start-page: 364S year: 2009 ident: bib24 article-title: Chromosome 17 polysomy: a unifying hypothesis underlying benefit from adjuvant anthracyclines? publication-title: Cancer Res contributor: fullname: Munro – volume: 15 start-page: 137 year: 2002 end-page: 145 ident: bib35 article-title: Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status publication-title: Mod Pathol contributor: fullname: Frenkel – volume: 3 start-page: 379 year: 2004 end-page: 398 ident: bib7 article-title: Targeted therapy in breast cancer—the HER-2/neu gene and protein publication-title: Mol Cell Proteomic contributor: fullname: Bloom – volume: 48 start-page: 787 year: 2006 end-page: 794 ident: bib16 article-title: Observer variation in immunohistochemical analysis of protein expression, time for a change? publication-title: Histopathology contributor: fullname: Tovey – volume: 28 start-page: 221 year: 2007 end-page: 228 ident: bib13 article-title: Does polysomy of chromosome 17 have a role in ERBB2 and topoisomerase II alpha expression? publication-title: Tumor Biol contributor: fullname: Corominas – volume: 12 start-page: 1081 year: 2001 end-page: 1089 ident: bib28 article-title: HER-2 and topo-isomerase II alpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide publication-title: Ann Oncol contributor: fullname: Gancberg – volume: 355 start-page: 1851 year: 2006 ident: 10.1016/S1470-2045(10)70006-1_bib14 article-title: Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa052084 contributor: fullname: Poole – volume: 25 start-page: 4423 year: 2007 ident: 10.1016/S1470-2045(10)70006-1_bib4 article-title: Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy publication-title: J Clin Oncol doi: 10.1200/JCO.2007.11.0973 contributor: fullname: Bartlett – volume: 26 start-page: 5638 year: 2008 ident: 10.1016/S1470-2045(10)70006-1_bib15 article-title: Recommendations for collection and handling of specimens from group breast cancer clinical trials publication-title: J Clin Oncol doi: 10.1200/JCO.2007.15.1712 contributor: fullname: Leyland-Jones – volume: 8 start-page: 1107 year: 2002 ident: 10.1016/S1470-2045(10)70006-1_bib27 article-title: HER-2 amplification and topoisomerase II{alpha} gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil publication-title: Clin Cancer Res contributor: fullname: Di Leo – volume: 2 start-page: 397 year: 2008 ident: 10.1016/S1470-2045(10)70006-1_bib2 article-title: Type I receptor tyrosine kinases as predictive or prognostic markers in early breast cancer publication-title: Biomarker Med doi: 10.2217/17520363.2.4.397 contributor: fullname: Spears – volume: 77 start-page: 109 year: 2003 ident: 10.1016/S1470-2045(10)70006-1_bib9 article-title: Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma publication-title: Breast Cancer Res Treat doi: 10.1023/A:1021399923825 contributor: fullname: Watters – volume: 3 start-page: 379 year: 2004 ident: 10.1016/S1470-2045(10)70006-1_bib7 article-title: Targeted therapy in breast cancer—the HER-2/neu gene and protein publication-title: Mol Cell Proteomic doi: 10.1074/mcp.R400001-MCP200 contributor: fullname: Ross – volume: 26 start-page: 5027 year: 2008 ident: 10.1016/S1470-2045(10)70006-1_bib12 article-title: Type I receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial publication-title: J Clin Oncol doi: 10.1200/JCO.2007.14.6597 contributor: fullname: Bartlett – volume: 354 start-page: 2103 year: 2006 ident: 10.1016/S1470-2045(10)70006-1_bib26 article-title: HER2 and responsiveness of breast cancer to adjuvant chemotherapy publication-title: N Engl J Med doi: 10.1056/NEJMoa054504 contributor: fullname: Pritchard – volume: 86 start-page: 197 year: 2004 ident: 10.1016/S1470-2045(10)70006-1_bib23 article-title: HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel publication-title: Breast Cancer Res Treat doi: 10.1023/B:BREA.0000036783.88387.47 contributor: fullname: Di Leo – volume: 264 start-page: 44 year: 2008 ident: 10.1016/S1470-2045(10)70006-1_bib5 article-title: Topoisomerase II alpha-positive and BRCA1-negative phenotype: association with favorable response to epirubicin-based regimens for human breast cancers publication-title: Cancer Letts doi: 10.1016/j.canlet.2008.01.015 contributor: fullname: Miyoshi – volume: 28 start-page: 221 year: 2007 ident: 10.1016/S1470-2045(10)70006-1_bib13 article-title: Does polysomy of chromosome 17 have a role in ERBB2 and topoisomerase II alpha expression? publication-title: Tumor Biol doi: 10.1159/000107583 contributor: fullname: Corzo – volume: 21 start-page: 458 year: 2003 ident: 10.1016/S1470-2045(10)70006-1_bib33 article-title: HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2003.04.021 contributor: fullname: Moliterni – volume: 195 start-page: 422 year: 2001 ident: 10.1016/S1470-2045(10)70006-1_bib17 article-title: Evaluating HER2 amplification and overexpression in breast cancer publication-title: J Pathol doi: 10.1002/path.971 contributor: fullname: Bartlett – volume: 156 start-page: 839 year: 2000 ident: 10.1016/S1470-2045(10)70006-1_bib34 article-title: Amplification and deletion of topoisomerase II alpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer publication-title: Am J Pathol doi: 10.1016/S0002-9440(10)64952-8 contributor: fullname: Jarvinen – volume: 69 start-page: 99S year: 2009 ident: 10.1016/S1470-2045(10)70006-1_bib30 article-title: A meta-analysis of phase III trials evaluating the predictive value of HER2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy publication-title: Cancer Res doi: 10.1158/0008-5472.SABCS-705 contributor: fullname: Di Leo – volume: 148 start-page: 2073 year: 1996 ident: 10.1016/S1470-2045(10)70006-1_bib8 article-title: Expression of topoisomerase II alpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer publication-title: Am J Pathol contributor: fullname: Jarvinen – volume: 26 start-page: 736 year: 2008 ident: 10.1016/S1470-2045(10)70006-1_bib6 article-title: HER-2 and topoisomerase II as predictors of response to chemotherapy publication-title: J Clin Oncol doi: 10.1200/JCO.2007.15.4716 contributor: fullname: Pritchard – volume: 101 start-page: 644 year: 2009 ident: 10.1016/S1470-2045(10)70006-1_bib25 article-title: Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djp067 contributor: fullname: O'Malley – volume: 100 start-page: 14 year: 2008 ident: 10.1016/S1470-2045(10)70006-1_bib29 article-title: HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djm252 contributor: fullname: Gennari – volume: 93 start-page: 387 year: 2006 ident: 10.1016/S1470-2045(10)70006-1_bib19 article-title: REporting recommendations for tumour MARKer prognostic studies (REMARK) publication-title: Br J Cancer doi: 10.1038/sj.bjc.6602678 contributor: fullname: McShane – volume: 11 start-page: 4835 year: 2005 ident: 10.1016/S1470-2045(10)70006-1_bib3 article-title: Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer? publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-05-0196 contributor: fullname: Tovey – volume: 44 start-page: 2791 year: 2008 ident: 10.1016/S1470-2045(10)70006-1_bib20 article-title: Topoisomerase II alpha as a marker predicting anthracyclines' activity in early breast cancer patients: Ready for the primetime? publication-title: Eur J Cancer doi: 10.1016/j.ejca.2008.09.014 contributor: fullname: Di Leo – volume: 23 start-page: 7483 year: 2005 ident: 10.1016/S1470-2045(10)70006-1_bib22 publication-title: J Clin Oncol doi: 10.1200/JCO.2005.11.007 contributor: fullname: Knoop – volume: 406 start-page: 747 year: 2000 ident: 10.1016/S1470-2045(10)70006-1_bib1 article-title: Molecular portraits of human breast tumours publication-title: Nature doi: 10.1038/35021093 contributor: fullname: Perou – volume: 15 start-page: 137 year: 2002 ident: 10.1016/S1470-2045(10)70006-1_bib35 article-title: Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status publication-title: Mod Pathol doi: 10.1038/modpathol.3880505 contributor: fullname: Wang – volume: 354 start-page: 2177 year: 2006 ident: 10.1016/S1470-2045(10)70006-1_bib21 article-title: Anthracyclines and the tailoring of treatment for early breast cancer publication-title: N Engl J Med doi: 10.1056/NEJMe068065 contributor: fullname: Piccart-Gebhart – volume: 92 start-page: 1991 year: 2000 ident: 10.1016/S1470-2045(10)70006-1_bib32 article-title: HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/92.24.1991 contributor: fullname: Paik – volume: 20 start-page: 133 year: 2001 ident: 10.1016/S1470-2045(10)70006-1_bib31 article-title: HER2 expression and anthracycline effect: results from the Naples GUN3 Randomized Trial publication-title: Proc Am Soc Clin Oncol contributor: fullname: De Laurentiis – volume: 12 start-page: 1081 year: 2001 ident: 10.1016/S1470-2045(10)70006-1_bib28 article-title: HER-2 and topo-isomerase II alpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide publication-title: Ann Oncol doi: 10.1023/A:1011669223035 contributor: fullname: Di Leo – volume: 48 start-page: 787 year: 2006 ident: 10.1016/S1470-2045(10)70006-1_bib16 article-title: Observer variation in immunohistochemical analysis of protein expression, time for a change? publication-title: Histopathology doi: 10.1111/j.1365-2559.2006.02412.x contributor: fullname: Kirkegaard – volume: 22 start-page: 1169 year: 2009 ident: 10.1016/S1470-2045(10)70006-1_bib10 article-title: Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event publication-title: Mod Pathol doi: 10.1038/modpathol.2009.78 contributor: fullname: Yeh – volume: 440 start-page: 1045 year: 2006 ident: 10.1016/S1470-2045(10)70006-1_bib11 article-title: DNA sequence of human chromosome 17 and analysis of rearrangement in the human lineage publication-title: Nature doi: 10.1038/nature04689 contributor: fullname: Zody – volume: 19 start-page: 441 year: 2000 ident: 10.1016/S1470-2045(10)70006-1_bib18 article-title: Sample size considerations for the evaluation of prognostic factors in survival analysis publication-title: Stat Med doi: 10.1002/(SICI)1097-0258(20000229)19:4<441::AID-SIM349>3.0.CO;2-N contributor: fullname: Schmoor – volume: 219 start-page: 16 year: 2009 ident: 10.1016/S1470-2045(10)70006-1_bib36 article-title: Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis publication-title: J Pathol doi: 10.1002/path.2574 contributor: fullname: Marchiò – volume: 69 start-page: 364S year: 2009 ident: 10.1016/S1470-2045(10)70006-1_bib24 article-title: Chromosome 17 polysomy: a unifying hypothesis underlying benefit from adjuvant anthracyclines? publication-title: Cancer Res doi: 10.1158/0008-5472.SABCS-6059 contributor: fullname: Bartlett |
SSID | ssj0017105 |
Score | 2.3996444 |
Snippet | Summary Background The NEAT/BR9601 trial showed benefit for addition of anthracyclines to cyclophosphamide, methotrexate, and fluorouracil (CMF) as adjuvant... The NEAT/BR9601 trial showed benefit for addition of anthracyclines to cyclophosphamide, methotrexate, and fluorouracil (CMF) as adjuvant treatment for early... |
SourceID | proquest crossref pubmed elsevier |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 266 |
SubjectTerms | Antibiotics, Antineoplastic - administration & dosage Antibiotics, Antineoplastic - pharmacology Antigens, Neoplasm - genetics Antineoplastic Combined Chemotherapy Protocols - pharmacology Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomarkers Biomarkers, Pharmacological Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - pathology Chemotherapy Chromosomes Disease-Free Survival DNA repair DNA Topoisomerases, Type II - genetics DNA-Binding Proteins - genetics Epirubicin - administration & dosage Epirubicin - pharmacology Female Gene Amplification Genes, erbB-2 - genetics Hematology, Oncology and Palliative Medicine Humans Immunohistochemistry Kinases Medical prognosis Medical research Middle Aged Multivariate Analysis Oligonucleotide Array Sequence Analysis Patient Selection Poly-ADP-Ribose Binding Proteins Predictive Value of Tests Prospective Studies Survival Analysis Tumor Cells, Cultured Tumors |
Title | Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601) |
URI | https://www.clinicalkey.es/playcontent/1-s2.0-S1470204510700061 https://dx.doi.org/10.1016/S1470-2045(10)70006-1 https://www.ncbi.nlm.nih.gov/pubmed/20079691 https://www.proquest.com/docview/200957181 |
Volume | 11 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Lb9NAEB7RVkJcEG9CIdoDh_Zg4vXa--CC0ipVBWpUlUTKbbW211JRSULsHPoP-NnM2GtzKtyslUcj74xnvp2dB8DHwmjjU19GCadrRsF5pE2WRqXLlNelyHRB8Y6rubxcpl9X2Srk5tQhrbK3ia2hLjcFxcgnFMXP0JDyL9tfEQ2NosvVMEHjAI44-TkqFD8fMjy46jIYeariiLqu_y3gmXwfFk94fKridhrNQ67pIejZuqCLZ_A0YEc27YT9HB759Qt4fBVux1_C7-sdPZMBYz8p7WZXs03FHM1CcMU9FUF6lqNxq26bz8wxZNgXWt7dsy2NL_Ilvt61KSFSRIds-Y2F5tl3bLa93e1zYsem5Y89ovCGLUiF2cl8Nl1Mzm7wqMJPX8HyYrY4v4zCpIWoQATVRAhKYp0jVnDKocxEWjpldFUUQgo8bQthpHEIlKiZXuIq6X2lXYXeL6-8E4gYX8PherP2b4GlRmeeWkxJY9K0iJ30RuUyKXMpc-GSEXzqN9luu4Yadsg0I6lYkgottVKxfASqF4Xtq0XRvvk6_Gy15bZObNxREzGeaFtoNgI9UAY80eEEi-7if0yPe6Hbgc-ggiN40-nB8AUU8cU94u_-SXcMT7rkA0phew-HzW7vPyCmafIxHKiVGrf6O4ajs9n8-uYPzxXwkQ |
link.rule.ids | 314,780,784,12056,12223,21388,27924,27925,31719,33266,33744,43310,43579,43805,73745,74014,74302 |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Lb9NAEB5BkYAL4k0ojz1waA8mXq-9Dy4oVKkCbSIEidTbam2vpaKShNg59B_ws5mx1-ZUuFkrj0beGc98OzsPgHeF0canvowSTteMgvNImyyNSpcpr0uR6YLiHfOFnK3SLxfZRcjNqUNaZW8TW0NdbgqKkY8pip-hIeUft78iGhpFl6thgsZtuINeX5FS65Mhw4OrLoORpyqOqOv63wKe8fdh8YjHxypup9Hc5Jpugp6tCzp9CA8CdmSTTtiP4JZfP4a783A7_gR-f93RMxkw9pPSbnY121TM0SwEV1xTEaRnORq36rL5wBxDhn2h5dU129L4Il_i612bEiJFdMhWZyw0z75i0-3lbp8TOzYpf-wRhTdsSSrMjhbTyXL86RseVfjxU1idTpcnsyhMWogKRFBNhKAk1jliBaccykykpVNGV0UhpMDTthBGGodAiZrpJa6S3lfaVej98so7gYjxGRysN2v_AlhqdOapxZQ0Jk2L2ElvVC6TMpcyFy4Zwft-k-22a6hhh0wzkoolqdBSKxXLR6B6Udi-WhTtm6_Dz1ZbbuvExh01EeOJtoVmI9ADZcATHU6w6C7-x_SwF7od-AwqOILnnR4MX0ARX9wj_vKfdG_h3mw5P7fnnxdnh3C_S0SgdLZXcNDs9v414psmf9Nq8R85gPEM |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Lb9swDCa2Dih2Gda9mnXtdNihPXixLFuWehnSLkG3rkGxJUBvgmzLQIcuyWLn0H_Qn13Slt1Tt5shmCAs0uQnig-AT7lW2sWuCCJO14yC80DpJA4Km6ROFSJROcU7LqbybB5_v0qufEuhyqdVdjaxMdTFMqcY-ZCi-AkaUj4sfVbE5dfJl9XfgAZI0UWrn6bxFJ7RkDlqo69O-2wPnrbZjDxOw4A6sD8U8wx_9YuHPDxKw2YyzWNu6jEY2rijyUt44XEkG7WC34EnbvEKti_8TflruLtc0zMZM_aHUnDWFVuWzNJcBJvfUkGkYxkauvK6PmaWIcOu6PLmlq1olJEr8PW2ZQmRIlJk83PmG2nfsPHqer3JiB0bFb83iMhrNiN1ZofT8Wg2PPmJxxZ-9Abmk_Hs9CzwUxeCHNFUHSBACVWGuMGmFuUn4sKmWpV5LqTAk7cQWmqLoIka60W2lM6VypboCbPSWYHo8S1sLZYLtwss1ipx1G5Kah3HeWil02kmoyKTMhM2GsDnbpPNqm2uYfqsM5KKIanQUiMVwweQdqIwXeUo2jpX-R-vMtxUkQlbaiLG020D0wagekqPLVrMYNB1_I_pXid00_Pp1XEA71o96L-Aor-4R_z9P-k-wjYqsPnxbXq-B8_bnATKbPsAW_V64_YR6tTZQaPE97Ms9TE |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Predictive+markers+of+anthracycline+benefit%3A+a+prospectively+planned+analysis+of+the+UK+National+Epirubicin+Adjuvant+Trial+%28NEAT%2FBR9601%29&rft.jtitle=The+lancet+oncology&rft.au=Bartlett%2C+John+MS&rft.au=Munro%2C+Alison+F&rft.au=Dunn%2C+Janet+A&rft.au=McConkey%2C+Christopher&rft.date=2010-03-01&rft.issn=1470-2045&rft.volume=11&rft.issue=3&rft.spage=266&rft.epage=274&rft_id=info:doi/10.1016%2FS1470-2045%2810%2970006-1&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_S1470_2045_10_70006_1 |
thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F14702045%2FS1470204510X71108%2Fcov150h.gif |